This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
It’s no secret that the world is amidst a climate crisis never before seen in our time. And our excessive resource consumption is to blame. But just exactly what resources are to blame might surprise you. Hint: fossil fuels are only one part of the problem.
Dr. Robert Lahita, the director of Saint Joseph's Institute for Autoimmune and Rheumatic Diseases, joined Cheddar to discuss the latest on omicron as the new variant has popped up in more than a dozen states so far. He emphasized that vaccinations should remain the priority despite efficacy against the new variant being unknown at this point.
Six states have confirmed cases of the new Omicron coronavirus variant, and this number is expected to grow. Cheddar's Hena Doba speaks with Dr. William Schaffner,
Professor of Preventive Medicine at Vanderbilt University Medical Center, on the latest developments.
Just days after the detection of the Omicron variant, the World Health Organization has agreed to start the process of establishing a global pandemic treaty or accord. Amy Maxmen, senior reporter for Nature, and Dr. Samuel Scarpino, managing director for the Rockefeller Foundation's Pandemic Prevention Institute, joined Cheddar to discuss this effort and what lessons can be learned from the many COVID-19 failures as the world prepares for future pandemics.
Local Bounti rang the opening bell December 3 in honor of its recent trading debut on the NYSE after closing a $1.1 billion SPAC deal. The company operates an indoor growing facility in Montana and aims to transform the production and delivery of local, fresh and sustainably-grown leafy greens. Craig Hurlbert, co-founder and co-CEO of Local Bounti, joined Cheddar to discuss the company's goals as a newly publicly-traded company.
Stephan Winkelmann, president of Bugatti Automobiles and CEO of Lamborghini, stopped by Cheddar to talk about Lamborghini's 2021 success after the luxury automaker set a company sales record on more than 6,9000 vehicles delivered. With climate change top of mind for the auto industry, Winkelmann also talked about Lamborghini's commitment to hybridizing its entire fleet. Still, when it comes to supercars, the legacy brand isn't quite ready to give up gasoline power, and according to the CEO, three new combustion engine vehicles will be available in 2022.
New York officials have confirmed five omicron COVID-19 cases in New York City and on Long Island after a Minnesota man who tested positive for the same variant said he attended a convention in November at the Jacob Javits Center in Manhattan.
It's Friday at long last. Jill and Carlo cover the latest on Omicron, including a possible superspreader event in NYC. Plus, previewing the November jobs report, a new Zoom feature no one asked for, and when it's no longer a good idea to eat Thanksgiving leftovers.
Three cases of the new omicron COVID-19 variant have been confirmed in the U.S. Cheddar speaks with global infection disease specialist Dr. Rajeev Fernando on how to prepare for a possible new coronavirus wave.
